Kibow Biotech Continues Research On Therapy For Renal Disease.
PA, 17 November 2003
by Wyn Snow, Managing Editor
Biotech's mission is to provide a simple to use, orally ingested,
friendly microbial and cost effective alternative treatment for
renal disease. The product will launch in July 2004. The company
is developing two distinct but highly integrated medical breakthrough
products. These are:
biopharmaceutical to be used as a complementary or adjunct therapeutic
drug for treating end-stage renal failure patients who require
nutraceutical dietary management product that will help augment
normal, healthy renal function for chronic kidney disease (CKD)
or diminished kidney function patients (pre-dialysis patients).
project, "A dietary supplement to augment kidney function" (Grant
# 5 R44 DK061873-03) has received its second year of phase II funding
by NIH. This continuation of its fast-track phase I and II Small
Business Innovation Research Grant (SBIR) is funded by the National
Institute of Diabetes Digestive and Kidney Diseases (NIDDK), a division
of the National Institute of Health.
the current award, Kibow has thus far secured a total of $1.9 million
grant funding from the federal governmental resources. After successful
completion of the phase II first year research and its progress,
NIDDK, NIH has showed their continued interest in Kibow's intriguing
and innovative method to treat uremia by awarding the last portion
of the phase II award of $500,000 from the original $1,076,056 grant.
company was already a recipient of an earlier SBIR phase I and II
fast-track grant award of $850,000 for the project entitled "Sorbents
& Engineered Bacteria as Gut-Based Uremia Therapy."
company was founded in October 1997 and is headquartered at the
science center in close proximity to University of Pennsylvania/Drexel
University, Philadelphia, PA. For more scientific information contact
Dr. N. Ranganathan,
Sr. VP (R&D) and Chief Scientific Officer at 215-966-6169.
Biotech, Inc. (www.kibowbiotech.com).